Guided Therapeutics (GTHP) Return on Capital Employed (2012 - 2025)

Guided Therapeutics has disclosed Return on Capital Employed across 14 years of filings, most recently posting 42.95% for Q4 2025.

• Return on Capital Employed for Q4 2025 came in at 42.95%, down 61.0% year-over-year; the trailing twelve-month figure through Dec 2025 was 42.95% (down 61.0% YoY), and the FY2025 annual result was 44.88%, down 63.0% from the prior year.
• Return on Capital Employed came in at 42.95% for Q4 2025 at Guided Therapeutics, up from 39.58% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 427.0% in Q1 2023 to a low of 22.15% in Q1 2021.
• The 5-year median for Return on Capital Employed is 55.27% (2021), against an average of 97.87%.
• Across the five-year window, Return on Capital Employed jumped 36926 bps in 2023 and sank 34797 bps in 2024, its largest moves.
• Guided Therapeutics' Return on Capital Employed stood at 60.65% in 2021, then jumped by 339 bps to 266.45% in 2022, then plunged by 57 bps to 113.83% in 2023, then tumbled by 62 bps to 43.56% in 2024, then fell by 1 bps to 42.95% in 2025.
• The last three Return on Capital Employed figures came in at 42.95% (Q4 2025), 39.58% (Q3 2025), and 41.89% (Q2 2025), per Business Quant data.